Cummings John H, Kong San Choon
Division of Pathology and Neuroscience, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
Novartis Found Symp. 2004;263:99-111; discussion 111-4, 211-8.
Probiotics and prebiotics are the sort of therapy that most patients with inflammatory bowel disease (IBD) wish for. They are without significant side effects, except possibly an increase in gas with prebiotics, and so far, appear to be entirely safe. However, are they effective? More than a dozen studies using probiotics in IBD have now been reported, and there is dear benefit in pouchitis and possibly also in Crohn's, although there are so many clinical types of this condition that a clear indication has yet to emerge. For ulcerative colitis (UC) more studies are needed. The use of prebiotics in IBD is only just starting, although significant effects on both the luminal and mucosa-associated flora have been demonstrated in healthy subjects. Antibiotics offer more certain hope in IBD treatment, although with a much greater risk of unwanted effects. Their efficacy in clinical studies varies, with Crohn's disease and pouchitis reporting more benefit than ulcerative colitis. However, the ideal combination of antibiotics, and rationale for their use has not been determined.
益生菌和益生元是大多数炎症性肠病(IBD)患者所期望的治疗方法。它们没有明显的副作用,除了益生元可能会导致气体增多,而且到目前为止,似乎完全安全。然而,它们有效吗?目前已经报道了十几项在IBD中使用益生菌的研究,在袋状结肠炎中确实有益处,在克罗恩病中可能也有益处,尽管这种疾病有很多临床类型,尚未出现明确的指征。对于溃疡性结肠炎(UC),还需要更多的研究。益生元在IBD中的应用才刚刚开始,尽管在健康受试者中已证明其对肠道菌群和黏膜相关菌群有显著影响。抗生素在IBD治疗中带来了更确切的希望,尽管不良反应的风险要大得多。它们在临床研究中的疗效各不相同,克罗恩病和袋状结肠炎报告的益处比溃疡性结肠炎更多。然而,抗生素的理想组合及其使用原理尚未确定。